Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (211-220 of 574) with videos related to

Pageof 58
Sort By:
Neuro-Oncology Practice|January 28, 2022
Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancerAnnemarie C Eggen, Nadine M Richard, Ingeborg Bosma, et al.
Journal of Pain and Symptom Management|March 8, 2020
Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain MetastasesAnnemarie C Eggen, Anna K L Reyners, Gerald Shen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical expertsNancee Pronsati, Geoffrey Liu, Todd M Bauer, et al.
Pharmacoepidemiology and Drug Safety|March 14, 2021
Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicineAmalia M Issa, Bruce Carleton, Tobias Gerhard, et al.
Clinical Lung Cancer|March 2, 2016
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse ModelPetra Martin, Erin Stewart, Nhu-An Pham, et al.
JTO Clinical and Research Reports|February 3, 2022
Effects of Ethnicity on Outcomes of Patients With <i>EGFR</i> Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical ResectionMike R Sung, Pascale Tomasini, Lisa W Le, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 18, 2017
Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaAndrew J Martin, Emma Gibbs, Katrin Sjoquist, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLCBarbara Melosky, Quincy S C Chu, Rosalyn A Juergens, et al.
Clinical Lung Cancer|May 28, 2018
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung CancerAlona Zer, Mike R Sung, Preet Walia, et al.
Pageof 58

Showing results (211-220 of 574) with videos related to

Sort By:
Pageof 58
Neuro-Oncology Practice|January 28, 2022
Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancerAnnemarie C Eggen, Nadine M Richard, Ingeborg Bosma, et al.
Journal of Pain and Symptom Management|March 8, 2020
Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain MetastasesAnnemarie C Eggen, Anna K L Reyners, Gerald Shen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical expertsNancee Pronsati, Geoffrey Liu, Todd M Bauer, et al.
Pharmacoepidemiology and Drug Safety|March 14, 2021
Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicineAmalia M Issa, Bruce Carleton, Tobias Gerhard, et al.
Clinical Lung Cancer|March 2, 2016
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse ModelPetra Martin, Erin Stewart, Nhu-An Pham, et al.
JTO Clinical and Research Reports|February 3, 2022
Effects of Ethnicity on Outcomes of Patients With <i>EGFR</i> Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical ResectionMike R Sung, Pascale Tomasini, Lisa W Le, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 18, 2017
Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaAndrew J Martin, Emma Gibbs, Katrin Sjoquist, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLCBarbara Melosky, Quincy S C Chu, Rosalyn A Juergens, et al.
Clinical Lung Cancer|May 28, 2018
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung CancerAlona Zer, Mike R Sung, Preet Walia, et al.
Pageof 58